BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17987251)

  • 1. Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients.
    Vepsäläinen S; Helisalmi S; Koivisto AM; Tapaninen T; Hiltunen M; Soininen H
    J Neurol; 2007 Nov; 254(11):1504-8. PubMed ID: 17987251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between somatostatin gene polymorphisms and sporadic Alzheimer's disease in Chinese population.
    Xue S; Jia L; Jia J
    Neurosci Lett; 2009 Nov; 465(2):181-3. PubMed ID: 19733630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl carboxypeptidase 1 (DCP1) and butyrylcholinesterase (BCHE) gene interactions with the apolipoprotein E epsilon4 allele as risk factors in Alzheimer's disease and in Parkinson's disease with coexisting Alzheimer pathology.
    Mattila KM; Rinne JO; Röyttä M; Laippala P; Pietilä T; Kalimo H; Koivula T; Frey H; Lehtimäki T
    J Med Genet; 2000 Oct; 37(10):766-70. PubMed ID: 11015454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CD33 rs3865444:C˃A polymorphism with a reduced risk of late-onset Alzheimer's disease in Slovaks is limited to subjects carrying the APOE ε4 allele.
    Javor J; Ďurmanová V; Párnická Z; Minárik G; Králová M; Pečeňák J; Vašečková B; Režnáková V; Šutovský S; Gmitterová K; Hromádka T; Peterajová Ľ; Shawkatová I
    Int J Immunogenet; 2020 Oct; 47(5):397-405. PubMed ID: 32333488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway.
    Sando SB; Melquist S; Cannon A; Hutton ML; Sletvold O; Saltvedt I; White LR; Lydersen S; Aasly JO
    BMC Neurol; 2008 Apr; 8():9. PubMed ID: 18416843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between the ApoE polymorphisms and the MRI-defined intracranial lesions in a cohort of southern China population.
    Li Z; Yang N; Lei X; Lin C; Li N; Jiang X; Wei X; Xu B
    J Clin Lab Anal; 2019 Sep; 33(7):e22950. PubMed ID: 31199015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haplotype analysis of APOE intragenic SNPs.
    Babenko VN; Afonnikov DA; Ignatieva EV; Klimov AV; Gusev FE; Rogaev EI
    BMC Neurosci; 2018 Apr; 19(Suppl 1):16. PubMed ID: 29745836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter polymorphism (-491A/T) in the APOE gene of Finnish Alzheimer's disease patients and control individuals.
    Helisalmi S; Hiltunen M; Valonen P; Mannermaa A; Koivisto AM; Lehtovirta M; Ryynänen M; Soininen H
    J Neurol; 1999 Sep; 246(9):821-4. PubMed ID: 10525981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-degrading enzyme and Alzheimer disease: a genetic association study in the Han Chinese.
    Bian L; Yang JD; Guo TW; Sun Y; Duan SW; Chen WY; Pan YX; Feng GY; He L
    Neurology; 2004 Jul; 63(2):241-5. PubMed ID: 15277615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease.
    Coon KD; Myers AJ; Craig DW; Webster JA; Pearson JV; Lince DH; Zismann VL; Beach TG; Leung D; Bryden L; Halperin RF; Marlowe L; Kaleem M; Walker DG; Ravid R; Heward CB; Rogers J; Papassotiropoulos A; Reiman EM; Hardy J; Stephan DA
    J Clin Psychiatry; 2007 Apr; 68(4):613-8. PubMed ID: 17474819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of novel quantitative traits-associated susceptibility loci for APOE ε 4 non-carriers of Alzheimer's disease.
    Jiang S; Yang W; Qiu Y; Chen HZ;
    Curr Alzheimer Res; 2015; 12(3):218-27. PubMed ID: 25731621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease.
    Lehtimäki T; Pirttilä T; Mehta PD; Wisniewski HM; Frey H; Nikkari T
    Hum Genet; 1995 Jan; 95(1):39-42. PubMed ID: 7814023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SIRT2 polymorphism rs10410544 and risk of Alzheimer's disease in two Caucasian case-control cohorts.
    Polito L; Kehoe PG; Davin A; Benussi L; Ghidoni R; Binetti G; Quadri P; Lucca U; Tettamanti M; Clerici F; Bagnoli S; Galimberti D; Nacmias B; Sorbi S; Guaita A; Scarpini E; Mariani C; Forloni G; Albani D
    Alzheimers Dement; 2013 Jul; 9(4):392-9. PubMed ID: 22651940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.
    Raygani AV; Zahrai M; Raygani AV; Doosti M; Javadi E; Rezaei M; Pourmotabbed T
    Neurosci Lett; 2005 Feb; 375(1):1-6. PubMed ID: 15664112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CDC2 I-G-T haplotype associated with the APOE epsilon4 allele increases the risk of sporadic Alzheimer's disease in Sicily.
    Bosco P; Caraci F; Copani A; Spada RS; Sortino MA; Salluzzo R; Salemi M; Nicoletti F; Ferri R
    Neurosci Lett; 2007 Jun; 419(3):195-8. PubMed ID: 17498878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flanking markers of cystatin c (CST3) gene do not show association with Alzheimer's disease.
    Helisalmi S; Väkevä A; Hiltunen M; Soininen H
    Dement Geriatr Cogn Disord; 2009; 27(4):318-21. PubMed ID: 19293566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease.
    Zhang Q; Yu JT; Zhu QX; Zhang W; Wu ZC; Miao D; Tan L
    Brain Res; 2010 Aug; 1348():216-21. PubMed ID: 20558149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ACT/AA polymorphism could duplicate the APOE*epsilon4-associated Alzheimer's disease risk].
    Hernández-Charro B; Moreno S; Valiente A; Manubens JM; Villar MD; Ramos-Arroyo MA
    Med Clin (Barc); 2004 Sep; 123(7):251-4. PubMed ID: 15482730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic risk score modifies the effect of APOE on risk and age onset of Alzheimer's disease.
    Shi Z; Yu H; Wu Y; Ford M; Perschon C; Wang C; Zheng SL; Xu J
    Clin Genet; 2019 Feb; 95(2):302-309. PubMed ID: 30460685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparan sulfate proteoglycan 2 polymorphism in Alzheimer's disease and correlation with neuropathology.
    Iivonen S; Helisalmi S; Mannermaa A; Alafuzoff I; Lehtovirta M; Soininen H; Hiltunen M
    Neurosci Lett; 2003 Dec; 352(2):146-50. PubMed ID: 14625044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.